AskAt 
Welcome,         Profile    Billing    Logout  
  Products    Diseases    Products    Trials    News 


12»
  • ||||||||||  Halaven (eribulin mesylate) / Eisai, grapiprant (RQ-00000007) / AskAt, Ikena Oncology, Maruishi Pharma
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer (clinicaltrials.gov) -  Sep 19, 2024   
    P1/2,  N=6, Terminated, 
    Future work should determine if early, effective treatment is of long-term benefit. N=25 --> 6 | Trial completion date: Dec 2025 --> Sep 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2025 --> Sep 2024; Termination was requested by study supporter IKENA oncology
  • ||||||||||  grapiprant (RQ-00000007) / AskAt, Ikena Oncology, Maruishi Pharma
    Trial completion, Trial completion date, Trial primary completion date, Metastases:  KEYNOTE-878: Grapiprant and Pembrolizumab in Patients With Advanced or Progressive MSS Colorectal Cancer (clinicaltrials.gov) -  Oct 24, 2023   
    P1b,  N=54, Completed, 
    Trial completion date: Sep 2024 --> Sep 2025 | Trial primary completion date: Jun 2024 --> Jun 2025 Active, not recruiting --> Completed | Trial completion date: Sep 2022 --> Mar 2023 | Trial primary completion date: Jun 2022 --> Mar 2023
  • ||||||||||  Halaven (eribulin mesylate) / Eisai, grapiprant (RQ-00000007) / AskAt, Ikena Oncology, Maruishi Pharma
    Enrollment closed:  Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer (clinicaltrials.gov) -  May 25, 2023   
    P1/2,  N=25, Active, not recruiting, 
    Further studies are needed to evaluate the efficacy of grapiprant in pigs. Recruiting --> Active, not recruiting
  • ||||||||||  grapiprant (RQ-00000007) / AskAt, Ikena Oncology, Maruishi Pharma
    Trial completion date, Trial initiation date, Trial primary completion date:  3D1002 in Combination With Oxycodone Hydrochloride Sustained-release Tablets in Patients With Moderate to Severe Cancer Pain (clinicaltrials.gov) -  Jan 4, 2023   
    P2a/2b,  N=177, Not yet recruiting, 
    AAT-008 potentially enhances the radiosensitivity of colon cancer cells, apparently by stimulating the immune system against the cancer cells. Trial completion date: Sep 2023 --> Sep 2024 | Initiation date: Sep 2022 --> Sep 2023 | Trial primary completion date: Jun 2023 --> Jun 2024
  • ||||||||||  grapiprant (RQ-00000007) / AskAt, Ikena Oncology, Maruishi Pharma
    Journal:  Grapiprant or carprofen following ovariohysterectomy in the cat: analgesic efficacy, hematological, biochemical and urinalysis evaluation. (Pubmed Central) -  Jul 28, 2022   
    Results of this preliminary study suggested both carprofen and grapiprant may be effective for postoperative pain following OVH in dogs; however, additional studies are warranted to determine grapiprant's effectiveness in a larger and more diverse population of dogs. Grapiprant did not promote adequate analgesia during the first 3 h postoperatively in cats undergoing ovariohysterectomy compared with carprofen, and no benefits were observed by administering grapiprant every 12 h.
  • ||||||||||  grapiprant (RQ-00000007) / AskAt, Ikena Oncology, Maruishi Pharma
    Trial completion date, Trial initiation date, Trial primary completion date:  3D1002 in Combination With Oxycodone Hydrochloride Sustained-release Tablets in Patients With Moderate to Severe Cancer Pain (clinicaltrials.gov) -  Jun 22, 2022   
    P2a/2b,  N=177, Not yet recruiting, 
    Grapiprant did not promote adequate analgesia during the first 3 h postoperatively in cats undergoing ovariohysterectomy compared with carprofen, and no benefits were observed by administering grapiprant every 12 h. Trial completion date: Apr 2023 --> Sep 2023 | Initiation date: Mar 2022 --> Sep 2022 | Trial primary completion date: Dec 2022 --> Jun 2023
  • ||||||||||  grapiprant (RQ-00000007) / AskAt, Ikena Oncology, Maruishi Pharma
    Trial completion date, Trial primary completion date, Metastases:  KEYNOTE-878: Grapiprant and Pembrolizumab in Patients With Advanced or Progressive MSS Colorectal Cancer (clinicaltrials.gov) -  Apr 22, 2022   
    P1b,  N=54, Active, not recruiting, 
    Further research including multidose assessments at this current dose with food, in vitro pharmacological characterization, and pharmacodynamic studies in this species are warranted. Trial completion date: Jun 2022 --> Sep 2022 | Trial primary completion date: Mar 2022 --> Jun 2022
  • ||||||||||  grapiprant (RQ-00000007) / AskAt, Ikena Oncology, Maruishi Pharma
    Review, Journal:  Grapiprant: A snapshot of the current knowledge. (Pubmed Central) -  Nov 29, 2021   
    The pharmacokinetics show discrepancies between animal species. The therapeutic efficacy seems more suited to chronic rather than acute pain.
  • ||||||||||  grapiprant (RQ-00000007) / AskAt, Ikena Oncology, Maruishi Pharma
    PK/PD data, Journal:  Tolerance and Pharmacokinetics of Galliprant™ Administered Orally to Collies Homozygous for MDR1-1Δ. (Pubmed Central) -  Nov 29, 2021   
    Self-liming vomiting events occurred at a numerically higher rate (2/8; 25%) in this group of P-gp-deficient dogs than seen in a clinical study (17%) composed of various dog breeds but limited numbers in this PK study make comparisons difficult. Grapiprant was otherwise well tolerated in collies homozygous for MDR1-1Δ despite increased drug exposure compared to dogs without this mutation.
  • ||||||||||  Halaven (eribulin mesylate) / Eisai, grapiprant (RQ-00000007) / AskAt, Ikena Oncology, Maruishi Pharma
    Enrollment open:  Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer (clinicaltrials.gov) -  Nov 22, 2021   
    P1/2,  N=25, Recruiting, 
    Grapiprant was otherwise well tolerated in collies homozygous for MDR1-1Δ despite increased drug exposure compared to dogs without this mutation. Not yet recruiting --> Recruiting
  • ||||||||||  grapiprant (RQ-00000007) / AskAt, Ikena Oncology, Maruishi Pharma
    PK/PD data, Journal:  Pharmacokinetics of grapiprant administered to red-tailed hawks (Buteo jamaicensis) after food was withheld for 24 hours. (Pubmed Central) -  Nov 4, 2021   
    Although the single dose of grapiprant (30 mg/kg) delivered into the crop achieved plasma concentrations > 164 ng/mL in the RTHAs, it was unknown whether this concentration would be therapeutic for birds. Further research that incorporates multidose assessments, safety monitoring, and pharmacodynamic data collection is warranted on the use of grapiprant in RTHAs from which food was withheld versus not withheld.
  • ||||||||||  grapiprant (RQ-00000007) / AskAt, Ikena Oncology, Maruishi Pharma
    Journal:  Determination of grapiprant plasma and urine concentrations in horses. (Pubmed Central) -  Jun 22, 2021   
    Oral administration of grapiprant (2 mg kg) in horses did not achieve those concentrations. The dose was well tolerated; therefore, studies with larger doses could be conducted.
  • ||||||||||  grapiprant (RQ-00000007) / AskAt, Ikena Oncology, Maruishi Pharma
    Trial completion date, Trial primary completion date, Metastases:  KEYNOTE-878: Grapiprant and Pembrolizumab in Patients With Advanced or Progressive MSS Colorectal Cancer (clinicaltrials.gov) -  May 25, 2021   
    P1b,  N=58, Recruiting, 
    The dose was well tolerated; therefore, studies with larger doses could be conducted. Trial completion date: Nov 2021 --> Jun 2022 | Trial primary completion date: Jul 2021 --> Mar 2022
  • ||||||||||  dexamethasone / Generic mfg.
    Preclinical, Journal:  New drugs for small animals in 2019 (Pubmed Central) -  May 11, 2021   
    One substance was authorized for an additional species: The antidiabetic protamine zinc insulin of human origin (ProZinc) is now additionally authorized for dogs. Additionally, one veterinary drug with a new combination of active ingredients (fluralaner + moxidectin), 5 agents in a novel pharmaceutical formulation (acepromazine, chloramphenicol, dexamethasone, metronidazole, torasemide), one drug (lidocaine) with a new route of administration, as well as one agent (apomorphine) in a new primary packaging with extended opening stability have been launched on the market for small animals.
  • ||||||||||  grapiprant (RQ-00000007) / AskAt, Ikena Oncology, Maruishi Pharma
    Journal:  NFκB-Activated COX2/PGE/EP4 Axis Controls the Magnitude and Selectivity of BCG-Induced Inflammation in Human Bladder Cancer Tissues. (Pubmed Central) -  Apr 7, 2021   
    PGE blockade allowed for the selectively enhanced migration of CTLs to the BCG-treated BlCa samples and eliminated the enhanced migration of Tregs. Since the balance between the CTLs and suppressive cells in the TME predicts the outcomes in patients with BlCa and other diseases, our data help to elucidate the mechanisms which limit the effectiveness of BCG therapies and identify new targets to enhance their therapeutic effects.
  • ||||||||||  grapiprant (RQ-00000007) / AskAt, Ikena Oncology, Maruishi Pharma
    Trial completion date, Trial termination, Trial primary completion date, Metastases:  KEYNOTE-888: Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma (clinicaltrials.gov) -  Feb 21, 2021   
    P1b/2,  N=18, Terminated, 
    Trial completion date: Nov 2021 --> Feb 2021 | Active, not recruiting --> Terminated | Trial primary completion date: Jul 2021 --> Feb 2021; Based on the totality of the generated combined safety and efficacy data in the interim period, the company decided to terminate the combination study in NSCLC patients. There are no subjects on study drug at this time or in the EOT Follow-up period.
  • ||||||||||  grapiprant (RQ-00000007) / AskAt, Ikena Oncology, Maruishi Pharma
    Trial completion date, Trial primary completion date, PD(L)-1 Biomarker, Metastases:  KEYNOTE-878: Grapiprant and Pembrolizumab in Patients With Advanced or Progressive MSS Colorectal Cancer (clinicaltrials.gov) -  Aug 8, 2020   
    P1b,  N=53, Recruiting, 
    Recruiting --> Active, not recruiting | N=41 --> 18 Trial completion date: Aug 2020 --> Nov 2021 | Trial primary completion date: Aug 2020 --> Jul 2021
  • ||||||||||  grapiprant (RQ-00000007) / AskAt, Ikena Oncology, Maruishi Pharma
    Enrollment change, Trial completion date, Trial primary completion date, PD(L)-1 Biomarker, Metastases:  KEYNOTE-888: Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma (clinicaltrials.gov) -  Aug 8, 2020   
    P1b/2,  N=41, Recruiting, 
    Trial completion date: Aug 2020 --> Nov 2021 | Trial primary completion date: Aug 2020 --> Jul 2021 N=25 --> 41 | Trial completion date: Sep 2020 --> Nov 2021 | Trial primary completion date: Sep 2020 --> Jul 2021
  • ||||||||||  Analgin (metamizole) / Sedico, grapiprant (RQ-00000007) / AskAt, Kyn Therap, Maruishi Pharma
    Review, Journal:  Antiinflammatory Drugs. (Pubmed Central) -  Nov 2, 2019   
    This article reviews the mechanisms of action, clinical use, and recent scientific evidence for the use of nonsteroidal antiinflammatory drugs, grapiprant, acetaminophen (paracetamol), metamizole (dipyrone), and corticosteroids in pain management. The discussion is presented with an emphasis on the treatment of acute pain.